Landos Biopharma, Inc. (NASDAQ:LABP) to Post FY2024 Earnings of ($2.03) Per Share, Leerink Partnrs Forecasts

Landos Biopharma, Inc. (NASDAQ:LABPFree Report) – Stock analysts at Leerink Partnrs boosted their FY2024 EPS estimates for shares of Landos Biopharma in a research report issued to clients and investors on Monday, February 5th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings of ($2.03) per share for the year, up from their previous forecast of ($2.25). The consensus estimate for Landos Biopharma’s current full-year earnings is ($3.41) per share. Leerink Partnrs also issued estimates for Landos Biopharma’s FY2025 earnings at ($1.30) EPS.

Landos Biopharma Price Performance

Landos Biopharma stock opened at $5.31 on Thursday. Landos Biopharma has a 1 year low of $2.33 and a 1 year high of $5.62. The stock has a market cap of $16.57 million, a price-to-earnings ratio of -1.41 and a beta of -0.53. The firm has a 50-day moving average of $4.45 and a two-hundred day moving average of $4.07.

Landos Biopharma (NASDAQ:LABPGet Free Report) last released its quarterly earnings data on Thursday, November 9th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.79) by ($0.15).

Institutional Investors Weigh In On Landos Biopharma

Large investors have recently modified their holdings of the business. Goldman Sachs Group Inc. raised its holdings in shares of Landos Biopharma by 119.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 42,800 shares of the company’s stock valued at $31,000 after purchasing an additional 23,263 shares in the last quarter. HRT Financial LP bought a new stake in shares of Landos Biopharma in the 4th quarter valued at about $26,000. Bank of America Corp DE raised its holdings in shares of Landos Biopharma by 80.4% in the 1st quarter. Bank of America Corp DE now owns 56,321 shares of the company’s stock valued at $83,000 after purchasing an additional 25,096 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Landos Biopharma by 30.6% in the 3rd quarter. Vanguard Group Inc. now owns 166,608 shares of the company’s stock valued at $108,000 after purchasing an additional 39,053 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Landos Biopharma by 99.0% in the 1st quarter. Renaissance Technologies LLC now owns 340,500 shares of the company’s stock valued at $502,000 after purchasing an additional 169,400 shares in the last quarter.

About Landos Biopharma

(Get Free Report)

Landos Biopharma, Inc, a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract.

Further Reading

Earnings History and Estimates for Landos Biopharma (NASDAQ:LABP)

Receive News & Ratings for Landos Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Landos Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.